![]() ![]() The budget for this project includes Working Group meetings, and a project leader. In this project, we propose to assemble a Working Group of ASIG in order to identify Australian centres currently performing ASTC in scleroderma, consider which patients are most likely to benefit from this therapy, discuss the specifics of transplantation with haematologist experts, review the outcomes of ASCT in Australian patients, and ultimately draft a position statement on the place of ASCT in the management of Australian scleroderma patients. Purpose of review: Evidence for hematopoietic stem cell transplantation (HCT) in autoimmune disease has been building since the 1990s however, many clinicians may not yet be aware of its applications to autoimmune disease. However, the selection of suitable patients and the use of optimal conditioning regimens requires further investigation, in order to minimise the risk of complications and mortality. Stem cell bone marrow transplantation is currently in the spotlight as a potential new treatment for scleroderma. Development of an ASIG position statement on Autologous Stem Cell Transplantation (ASCT) in scleroderma. Scleroderma Australia will commit $25,000 to this projectĢ. The budget for this project includes annual NT-proBNP testing in approximately 500 patients with scleroderma over 3 years (each test at a cost of $60), and a 0.8 FTE project coordinator. ![]() If the new screening algorithm is shown to be feasible for roll-out in the community, the case for the listing of NT-proBNP on the Medicare Benefits Schedule will be strengthened. In this project, we propose to implement the algorithm in rheumatology practices in Queensland that fall within the catchment area of 4 major hospitals in Brisbane, to which patients who screen positive can then be referred for further evaluation. This new algorithm incorporates a blood test for NT-proBNP and lung function tests as the first step in screening, shifting the focus away from echocardiography of the heart which may not be accessible to all patients. Implementation and feasibility testing of the new Australian Scleroderma Interest Group algorithm for pulmonary arterial hypertension screening.ĪSIG has published a new screening algorithm for PAH screening in scleroderma to allow early detection of this serious complication and initiation of life-saving therapy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |